Lake Street resumed coverage on Strata Critical Medical with a new price target
$SRTA
Transportation Services
Consumer Discretionary
Lake Street resumed coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $8.00 | Buy | Lake Street |
Lake Street resumed coverage of Strata Critical Medical with a rating of Buy and set a new price target of $8.00
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Strata Critical Medical, Inc. ("Strata" or the "Company"), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 3, 2025. Mr. Cook has also been appointed to the Compensation and Nominating and Corporate Governance Committees. Mr. Cook is the President and Chief Executive Officer of Vail Health, a nonprofit community health care system headquartered in Vail, Colorado. "We are very excited to welcome Will Cook to our board of directors," said Melissa Tomkiel, Strata's Co-Chief Executive Office
Event highlights multiple ongoing industry growth catalysts and a range of factors that should enable Strata to grow faster than the overall marketTeam defines roll-up opportunity, acquisition philosophy and priority targets for $200 million of estimated cash available for deployment through 2029New 2026 financial guidance and medium-term financial framework targets a sustained high-teens target CAGR(1) for Adjusted EBITDA on an organic basisAdjusted EBITDA expected to double organically(1) by 2029, before capital deployment NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (NASDAQ:SRTA, ", Strata", or the ", Company", )) is hosting its 2025 Investor Day today at t
Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
4 - Strata Critical Medical, Inc. (0001779128) (Issuer)
8-K - Strata Critical Medical, Inc. (0001779128) (Filer)
8-K/A - Strata Critical Medical, Inc. (0001779128) (Filer)
S-8 - Strata Critical Medical, Inc. (0001779128) (Filer)
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Strata Critical Medical, Inc. ("Strata" or the "Company"), a leading provider of logistics and medical services in the organ transplant industry, today announced the appointment of Will Cook to the Board, effective December 3, 2025. Mr. Cook has also been appointed to the Compensation and Nominating and Corporate Governance Committees. Mr. Cook is the President and Chief Executive Officer of Vail Health, a nonprofit community health care system headquartered in Vail, Colorado. "We are very excited to welcome Will Cook to our board of directors," said Melissa Tomkiel, Strata's Co-Chief Executive Office
Revenue increased 36.7% year-over-year to $49.3 million in Q3 2025 and grew 29.0% excluding the impact of the Keystone acquisition Net loss increased to $(9.7) million in Q3 2025 versus $(5.6) million in the prior year periodMedical Segment Adjusted EBITDA increased 93.5% in Q3 2025 to $7.6 million versus the prior year period and increased 80.2% excluding the impact of the Keystone acquisition(1)Medical Segment Adjusted EBITDA margin excluding Keystone increased to 15.1% in Q3 2025(1)Raised 2025 revenue guidance to $185-195 million, reaffirmed Adjusted EBITDA rangeInvestor Day scheduled for November 17th 2025; will introduce 2026 guidance and medium term financial targets NEW YORK, Nov. 1
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Strata Critical Medical. (NASDAQ:SRTA, "Strata" or the "Company")), will release financial results for the third quarter ended September 30, 2025 on Monday, November 10, 2025 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. To join the live call, please register here. Upon registration, a dial-in and unique PIN will b